Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 8

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 8
---
31, 2024, filed with the SEC on March 3, 2025 and the Company’s annual meeting proxy statement on Schedule 14A filed with the SEC on April 29, 2025. Information regarding subsequent changes to the holdings of the Company’s securities by the Company’s directors and executive officers can be found in filings on Forms 3, 4, and 5, which are available on the Company’s website at www.reparex.com or through the SEC’s website at www.sec.gov. Additional information regarding the identity of the participants in the proxy solicitation and a description of their direct and indirect interests in the Transaction, by security holdings or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC in connection with the Transaction. Copies of these documents may be obtained, free of charge, from the SEC or the Company as described in the preceding paragraph.

| Item 9.01 | Financial Statements and Exhibits. |

(d) Exhibits

| Exhibit 
 No.     
 2.1     
 10.1    |     | Description                                                                                                                                                        
 Arrangement Agreement, dated November 14, 2025, by and among XenoTherapeutics, Inc., Xeno Acquisition Corp., Repare Therapeutics Inc. and XOMA Royalty Corporation 
 Form of Voting and Support Agreement, dated as November 14, 2025, by and between certain Shareholders and Xeno Acquisition Corp.                                   |
|:--------|:----|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 104     |     | Cover Page Interactive Data File (embedded within the Inline XBRL document)                                                                                        |

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| REPARE THERAPEUTICS INC. |     |                                        |
| By:                      |     | /s/ Steve Forte                        |
|                          |     | Steve Forte President, Chief Executive 
 Officer and Chief Financial Officer    |

Dated: November 17, 2025

Exhibit 2.1

EXECUTION VERSION

[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) customarily and actually treated by the registrant as private or confidential.

ARRANGEMENT AGREEMENT

between

XENOTHERAPEUTICS, INC.

– and –

X